Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey.

Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. The adverse impact of measurable residual disease (MRD) on outcomes after AML directed therapy is well recognized [[1]]. [Extracted from the article]